Investor Relations

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Stock Quotes

  o NYSE MKT: CVM  
  o NYSE MKT: CVM WS  

Press Releases

  o Press Releases  
  APRIL 14, 2014
NEW STORY CEL-SCI Corporation Prices $10 Million Public Offering of Common Stock and Six Month Warrants
  APRIL 11, 2014
NEW STORY CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Six Month Warrants
  APRIL 8, 2014
NEW STORY Henry Ford Health System of Detroit to Enroll and Treat Patients in CEL-SCI's Phase III Head and Neck Cancer Clinical Trial
  APRIL 2, 2014
NEW STORY Arizona Cancer Research Alliance & 21st Century Oncology to Enroll Patients in CEL-SCI's Global Phase III Head and Neck Cancer Trial
  APRIL 1, 2014
NEW STORY CEL-SCI Reports March 2014 is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial
  MARCH 4, 2014
NEW STORY First U.S. Clinical Site Opens for CEL-SCI'S Global Phase III Immunotherapy Head and Neck Cancer Trial Expansion
  FEBRUARY 27, 2014
NEW STORY CEL-SCI Reports 146 Patients Enrolled in its Phase III Immunotherapy Head and Neck Cancer Trial
  FEBRUARY 11, 2014
NEW STORY CEL-SCI Corporation Reports First Quarter 2014 Financial Results
  FEBRUARY 4, 2014
NEW STORY CEL-SCI Corporation Receives Approval for Listing and Trading of Warrants from the NYSE MKT under the Ticker Symbol "CVM WS"
  FEBRUARY 3, 2014
NEW STORY U.S. Navy Approves Start of CEL-SCI's Phase I Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients

Frequently Asked Questions

  o Reverse Stock Split  
       
 

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com